Clinical Study Of Jiawei Sanxian Decoction On Spleen-kidney Yang Deficiency Myelosuppression After Chemotherapy In Cervical Cancer

Objective: To observe the clinical efficacy and safety of Jiawei Sanxian Decoction on Spleen-Kidney deficiency myelosuppression after chemotherapy in cervical cancer,therefore,it is can confirmed that Chinese medicine can play a role in reducing toxicity and increasing efficacy in cancer treatment.Method: Select 60 patients who meet the inclusion criteria,then put them into two groups by randomized control,30 cases in treatment group and 30 cases in control group.The treatment group: Taking Jiawei Sanxian Decoction(150ml/bag,1 bag/time,3 times/day);The control group: Taking Jianpi Yishen Particles(30g/time,2 times/day).Both groups took 14 days as a course of treatment and observed two courses of treatment.At last,we evaluate the efficacy of myelosuppression、TCM syndrome scores and efficacy、KRS score and safety indicators before and after treatment in both groups,and through statistical methods to make efficacy evaluation.Results: This study compares the basic conditions of two groups when they are enrolled in the group.There are no significant differences in statistical analysis and they are comparable.1.Blood routine:(1)The T-test of independent samples showed that there was no significant difference in WBC,PLT,HB,and N before treatment between the two groups(P>0.05),and they were comparable.(2)On the 7th day of treatment,the WBC,PLT,HB,and N of the two groups were decreased in different degrees,and the decrease in the treatment group was significantly smaller than that in the control group.(3)On the 14 th day of treatment,the WBC,PLT,HB,and N of the two groups were increased in different degrees,and the increase in the treatment group was significantly greater than that in the control group.(4)On the 21 st day of treatment,WBC,PLT,HB,and N in the two groups were not significantly different from those before treatment(P>0.05),but the control group was significantly lower than before treatment(P<0.05),suggesting that the treatment group was better than the control group in the treatment of myelosuppression.(5)After treatment,the improvement rates of bone marrow suppression in the treatment group and the control group were 93.33% and 53.33%,respectively.After chi-square test,the difference between the two groups was statistically significant(P<0.05),suggesting that the treatment group was superior to the control group in improving bone marrow suppression.2.TCM syndrome scores:(1)After independent sample T test,the scores of TCM syndromes before and after treatment in the two groups were statistically different(P<0.05),suggesting that both groups of treatment can improve TCM syndromes.(2)After treatment,the scores of TCM syndrome were statistically significant(P<0.05),and the treatment group was superior to the control group.?(3)After treatment,the improvement rates of the clinical efficacy of the treatment group and the control group were 83.33% and 56.67%,respectively.After chi-square test,the difference between the two groups was statistically significant(P<0.05),suggesting that the treatment group was superior to the control group in improving clinical efficacy.3.KRS scores:(1)According to the independent sample T test,there was a statistically significant difference in the KRS scores before and after treatment between the two groups(P<0.05),suggesting that both groups can improve KRS scores.(2)After treatment,there was a statistically significant difference between the KRS score groups(P<0.05),and the treatment group was superior to the control group.(3)After treatment,the stable rates of quality of life in the treatment group and control group were 86.67% and 60%,respectively.After chi-square test,the difference between the two groups was statistically significant(P<0.05),suggesting that the treatment group was superior to the control group in improving the quality of life.4.Safety indicators: After treatment,independent test T test showed no significant difference in safety indicators between the two groups((P<0.05)),suggesting that the safety indicators of both groups were within the normal range after treatment.Conclusion:(1)Jiawei Sanxian Decoction can effectively reduce the degree of myelosuppression after chemotherapy in cervical cancer.(2)Jiawei Sanxian Decoction can reduce toxic side effects after chemotherapy,improve clinical symptoms of traditional Chinese medicine so as to improve therapeutic efficacy,enhance patient immunity and improve quality of life.(3)Jiawei Sanxian Decoction is safe and feasible without obvious toxic and side effects.It can play a significant role in reducing toxicity and increasing efficacy in the treatment of cervical cancer after chemotherapy,which is worthy of clinical reference and application.